USA flag logo/image

An Official Website of the United States Government

Development of Antipeptide Antibodies as Immunodiagnostic Probes

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
22476
Program Year/Program:
1993 / SBIR
Agency Tracking Number:
22476
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANATRACE, INC.
ANATRACE, INC. 26111 Miles Rd Cleveland, OH 44128 5933
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1993
Title: Development of Antipeptide Antibodies as Immunodiagnostic Probes
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

PRINCIPAL INVESTIGATOR: Reynolds, Steven H. AWARDEE ORGANIZATION: Life Sciences, Inc. 2900 72nd Street, North St. Petersburg, FL 33710 TELEPHONE NUMBER: (813) 345-9371 AWARDEE NUMBER: 200-93-0680 Tuberculosis is reemerging as a health threat in the United States. Primary reasons include the susceptibility of HIV-infected persons, the lack of rapid and effective diagnostic tests, and recent outbreaks of drug-resistant strains. The objective of this award is to produce monoclonal antibodies for the development of diagnostic immunoassays for detection of M. tuberculosis in clinical specimens, for diagnosis of infection, and for identification of drug-resistant strains. Superoxide dismutase and P32 antigen are secreted from viable M. tuberculosis cells, and may provide unique diagnostic markers. Decreased catalase/peroxidase activity, both with and without gene deletion, has been associated with drug-resistant strains. Peptides from these three M. tuberculosis proteins will be used as immunogens for the generation of site-specific monoclonal antibodies (Mabs). Phase I efforts will (1) provide will-characterized Mabs to these M. tuberculosis antigens, and (2) provide initial development of immunoassays utilizing these Mabs. Further development of diagnostic immunoassays, including testing of clinical samples, will occur in Phase II. The production of diagnostic test kits will provide rapid and sensitive methods for screening clinical specimens for M. tuberculosis, a technology that is currently not available.

Principal Investigator:

Don N. Gray
4198913037

Business Contact:

Small Business Information at Submission:

Anatrace, Inc.
1280 Dussel Dr. Maumee, OH 43537

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No